LONDON – Oxular Ltd. has raised $37 million in a series B, enabling the company to take OXU-001, its long-acting treatment for diabetic macular edema (DME) into phase II development later this year.

Big name investors think January AI Inc. is onto something sweet with its breakthrough diabetes management technology. Investors added $8.8 million to the company's finances, bringing its total capital raised to date to $21 million. Felicis Ventures, which previously invested in Fitbit and Modern Health, joined Hand Capital and Marc Benioff in the latest round.

HONG KONG – Vuno Inc. saw its shares soar on their first day of trading on the Kosdaq board with a $33.4 million IPO. The shares closed at ₩32,150 (US$28.89) on Feb. 26. Vuno had priced the 1.8 million new shares on offer at ₩21,000, exceeding its desired range of ₩15,000 to ₩19,500 and raising ₩37.8 billion, or $33.4 million, to boot.

Truvian Sciences Inc. has closed more than $105 million in an oversubscribed series C financing round that will help jumpstart the evaluation of the company’s automated benchtop blood testing system. The round was led by TYH Ventures, Glen Tullman of 7wireventures, and Wittington Ventures.

HONG KONG – Wuxi Diagnostic Investment (Cayman) Ltd. has raised $150 million in a series B financing round, while netting a number of new investors along the way. The new investors to come on board include Thermo Fisher Scientific Inc., Shiyu Capital, ABC International Holdings Ltd., Sunland Capital and CCBI Tech Venture.

HONG KONG – The third pre-revenue med-tech firm to list on the Hong Kong Stock Exchange in a month, New Horizon Health Technology Co. Ltd. raised HK$1.9 billion (US$245.08 million) in an IPO that began trading Thursday, Feb. 18. New Horizon placed 76.6 million shares at HK$26.66 apiece and said part of the funds will help the company commercialize its FIT-DNA test Coloclear to screen for colorectal cancer.